A detailed history of Main Street Group, LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Main Street Group, LTD holds 850 shares of GILD stock, worth $76,916. This represents 0.03% of its overall portfolio holdings.

Number of Shares
850
Previous 1,650 48.48%
Holding current value
$76,916
Previous $113,000 37.17%
% of portfolio
0.03%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $53,272 - $67,192
-800 Reduced 48.48%
850 $71,000
Q2 2024

Aug 05, 2024

SELL
$63.15 - $72.88 $45,531 - $52,546
-721 Reduced 30.41%
1,650 $113,000
Q1 2024

May 14, 2024

BUY
$71.58 - $87.29 $55,188 - $67,300
771 Added 48.19%
2,371 $173,000
Q4 2023

Feb 15, 2024

BUY
$73.27 - $83.09 $117,232 - $132,944
1,600 New
1,600 $130 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Main Street Group, LTD Portfolio

Follow Main Street Group, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Main Street Group, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Main Street Group, LTD with notifications on news.